
Obesity pills from Eli Lilly, Novo Nordisk near US launch
Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medications: pills. Both companies expect to launch oral obesity drugs in the U.S. next year, once regulators approve them. Daily pills could introduce more people to GLP-1s, the class of medicine that’s best known for weekly shots. But…